New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2014
07:04 EDTTRVNTrevena initiates TRV734 clinical development
Trevena announced the initiation of its first Phase 1 trial for TRV734. TRV734 is being developed to optimize analgesia while minimizing on-target gastrointestinal and respiratory effects through its novel biased ligand mechanism at the mu-opioid receptor. TRV734 takes advantage of the same receptor specificity mechanism as does Trevena’s Phase 2 clinical candidate, TRV130. The main objective of this first-in-human trial is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of TRV734 in healthy subjects. The potentially efficacious dose range of TRV734 will also be evaluated using pupilometry, a validated biomarker for mu-opioid receptor engagement.
News For TRVN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 18, 2015
07:06 EDTTRVNTrevena reports Q4 EPS (45c), consensus (52c)
Cash, cash equivalents and marketable securities were $106.9M as of December 31. "We are on track to complete our ongoing Phase 2b soft-tissue surgery trial and are continuing to plan for the Phase 3 program," said the company.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use